Merck begins construction of $3 billion manufacturing facility in Virginia

Core Viewpoint - Merck has initiated the construction of a $3 billion pharmaceutical manufacturing facility in Elkton, Virginia, as part of its broader strategy to invest over $70 billion in expanding domestic manufacturing capabilities [1] Group 1: Company Developments - The new facility in Elkton, Virginia, represents a significant investment by Merck in the U.S. pharmaceutical manufacturing sector [1] - This construction is part of a larger commitment by Merck to enhance its domestic manufacturing infrastructure [1] Group 2: Industry Context - The investment aligns with a growing trend among pharmaceutical companies to increase domestic production capabilities in response to global supply chain challenges [1] - Merck's $70 billion investment indicates a strong confidence in the U.S. market and aims to bolster the pharmaceutical industry's resilience [1]